Current read
Early human evidence from 1 study records, 64 active source records, 26 rapid briefs, and 0 timeline events. Evidence maturity is 52/100, human translation signal is 60/100, and frontier activity is extreme (100/100). Frontier activity means research movement, not settled human proof. Editorial launch override: Early human evidence because The current graph has live regenerative-medicine and early human translation signals, but not enough mature functional outcome evidence to call this clinical traction.
Human evidence exists, but durability, endpoint quality, or population fit still limits the claim.
Commercial bias penalty: 100/100. Confidence: 43/100. Frontier activity means research movement, not settled human proof.
Why this row matters
DNA methylation clocks, partial reprogramming, and attempts to reset age-linked cell state without losing identity. The map tracks whether this lane is moving from biological plausibility toward outcomes people can responsibly discuss.
Current human translation
Human translation is 36/100 based on human-facing studies, clinical/regulatory sources, claims, and published coverage.
Main approaches being tracked
DNA methylation clocks, partial reprogramming, retinal rejuvenation trials.
What would move this row up?
Current bottleneck
human translation
Milestones that would move this row up
What could move it down
- Safety failures that limit tissue-specific reprogramming
- Clock changes fail to translate into functional outcomes
Row movement
Mini timeline
Newest graph events across studies, sources, briefs, claims, and timeline records
Evidence that would change the map
- Raise evidence maturity from 52/100 with better controlled studies or stronger replication.
- Raise human translation from 36/100 with outcomes that matter in people, not only biomarkers or mechanisms.
- Preserve safety discipline with clearer limitations, contraindications, and overclaim boundaries as activity grows.
What not to overclaim
- Do not frame clock movement as whole-body age reversal.
- Do not generalize one tissue or early safety trial to systemic rejuvenation.
Research map
Related studies
Study records matched through topic tags, intervention IDs, source IDs, related content, or row-specific tags.
Useful source library entries
Related briefs
First Child Received Experimental Gene Therapy for Cockayne Syndrome
Riaan Singh Digeorge became the first reported patient to receive experimental AAV9 gene therapy for Cockayne syndrome after a parent-led development effort.
Why now
The first-patient milestone turns an ultra-rare parent-led research program into a live human gene-therapy story.
- Overclaim risk
- high
- Primary source
- Official
- Published
- Jul 5, 2026
FDA Expanded CRISPR Therapy to Children as Young as 2
Casgevy's label expansion moves CRISPR-based treatment access earlier for some children with sickle cell disease or transfusion-dependent beta thalassemia, but the treatment remains intensive and transplant-like.
Why now
The age expansion moves CRISPR medicine from teens and adults into much younger children for two severe inherited blood disorders.
- Overclaim risk
- high
- Primary source
- Official
- Published
- Jul 5, 2026
FDA Warns on Unapproved Cell and Tissue Products After Death Reports
FDA says unapproved human cell and tissue products marketed online may pose serious risks, including reports of patient deaths after use.
Why now
The gray-market regenerative medicine boom needs a clean evidence boundary alongside real cell and gene therapy breakthroughs.
- Overclaim risk
- medium-high
- Primary source
- Official
- Published
- Jun 30, 2026
Rett Gene Therapy Shows Developmental Milestone Gains in Early Trial
Neurogene says 10 Rett syndrome participants treated with NGN-401 gained developmental milestones through up to 30 months of follow-up.
Why now
Rett stories are emotionally powerful because development can regress after early childhood milestones.
- Overclaim risk
- high
- Primary source
- Trade news
- Published
- Jun 30, 2026
Parent-Led FOXG1 Gene Therapy Moves Toward Patient Trial
CIRM awarded $4.9 million to advance FRF-001, an AAV9 gene therapy for FOXG1 syndrome, through a Phase 1/2 clinical trial.
Why now
Parent-led foundations are increasingly becoming drug-development engines for devastating rare pediatric disorders.
- Overclaim risk
- high
- Primary source
- Official
- Published
- Jun 30, 2026
Epigenetic Gene Therapy Shows Early Muscle Gains in FSHD Patients
Epicrispr says its one-time EPI-321 therapy increased lean muscle volume in three patients with facioscapulohumeral muscular dystrophy.
Why now
Epigenetic editing is a new category readers will share, especially with early muscle-volume signals.
- Overclaim risk
- high
- Primary source
- Trade news
- Published
- Jun 30, 2026
Related published coverage
Published coverage contributes to coverage depth, not evidence maturity by itself.
Does Cannabis Shrink Your Brain?
A viral claim turns cannabis brain research into a one-line shrinkage scare. The evidence is messier: blood flow, activation, volume, cognition, age, dose, and heavy-use patterns are not interchangeable.
VV Signal Score
58
Early or context-dependent
- Sources
- 10
- Studies
- 7
- Claims
- 7
Claim ledger
Related claims
Claim ledger records matched by topic, intervention, study, or source links.
cannabis: The broad claim that cannabis shrinks your brain overstates
The broad claim that cannabis shrinks your brain overstates a mixed evidence base and swaps endpoints such as perfusion, activation, volume, and cognition.
cannabis: Cannabis brain-volume evidence varies by population, exposure pattern, age
Cannabis brain-volume evidence varies by population, exposure pattern, age at first use, co-use, measurement method, and confounding.
cannabis: Older-adult cannabis brain-volume counter-signals break the simple shrinkage meme
Older-adult cannabis brain-volume counter-signals break the simple shrinkage meme but do not prove cannabis protects the aging brain.